Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, Glenmark Life Sciences has informed that a meeting of the Board of Directors will be held on Thursday, October 24, 2024, to consider and approve the Unaudited Financial Results, of the Company for the second quarter and half year ended 30th September, 2024. Further, as per the ‘Code of Conduct for Prevention of Insider Trading’ and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has intimated its ‘designated persons’ regarding the closure of the Trading Window from September 30, 2024 to October 26, 2024 for the purpose of approval of Unaudited Financial Results for second quarter and half year ended September 30, 2024.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: